Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Net sales totaled $16.2 million in Q2 2025, Net sales increased 23% in the second quarter. This marks the third straight quarter of year-over-year revenue growth. OEM Net Sales-- OEM segment net sales ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the 'Company”) today reported results for the first quarter fiscal year 2026, which ended June 29, 2025.

Discover key insights from Arcturus Therapeutics' Q2 2025 earnings call, featuring updates on CF and OTC programs, vaccine progress, and ...

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the "Company") today reported results for the first quarter fiscal year 2026, which ended June 29, 2025. First ...

Q1 2026 Earnings Call Transcript August 8, 2025 Under Armour, Inc. misses on earnings expectations. Reported EPS is $0.02 EPS ...

Q2 2025 Management View James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.